Parkinson Protein 2, E3 Ubiquitin Protein Ligase (Parkin) (PARK2) Peptid
Kurzübersicht für Parkinson Protein 2, E3 Ubiquitin Protein Ligase (Parkin) (PARK2) Peptid (ABIN936245)
Target
Spezies
Quelle
Applikation
-
-
Protein-Typ
- Synthetic
-
Sequenz
- YTRYQQYGAE ECVLQMGGVL CPRPGCGAGL LPEQGQRKVT CEGGNGLGCG
-
Produktmerkmale
-
A synthetic peptide for use as a blocking control in assays to test for specificity of Park2 antibody,
Alternative Names: Park2 control peptide, Park2 antibody Blocking Peptide, Anti-Park2 Blocking Peptide, Parkinson disease, autosomal recessive, juvenile 2, parkin Blocking Peptide, MGC130518 Blocking Peptide, PRKN Blocking Peptide, Park2, Park-2, Park 2, Park-2 Blocking Peptide, Park 2 Blocking Peptide -
Aufreinigung
- Serum
-
-
-
-
Applikationshinweise
- Optimal conditions should be determined by the investigator
-
Beschränkungen
- Nur für Forschungszwecke einsetzbar
-
-
-
Format
- Lyophilized
-
Rekonstitution
- Add 100 µL of distilled water for a final peptide concentration is 1 mg/mL.
-
Buffer
- PBS
-
Handhabung
- Avoid repeated freeze/thaw cycles.
-
Lagerung
- -20 °C
-
Informationen zur Lagerung
- Store at -20 °C long term.
-
-
- Parkin (PARK2) (Parkinson Protein 2, E3 Ubiquitin Protein Ligase (Parkin) (PARK2))
-
Hintergrund
- Park2 functions within a multiprotein E3 ubiquitin ligase complex, catalyzing the covalent attachment of ubiquitin moieties onto substrate proteins. These substrates include SYT11, CCNE1, GPR37, STUB1, a 22 kDa O-linked glycosylated isoform of SNCAIP, SEPT5 and AIMP2. Park2 may play a more general role in the ubiquitin proteasomal pathway by participating in the removal and/or detoxification of abnormally folded or damaged protein. Park2 limits the production of reactive oxygen species (ROS).
-
Molekulargewicht
- 51 kDa
Target
-